» Articles » PMID: 16730260

Cancer Immunosurveillance and Immunoediting: the Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity

Overview
Journal Adv Immunol
Date 2006 May 30
PMID 16730260
Citations 341
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular transformation and tumor development result from an accumulation of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate as to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, we discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance function) but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.

Citing Articles

Uncovering the Heterogeneity of Signaling Pathways in Skin Cutaneous Melanoma: Insights into Prognostic Values and Immune Interactions.

Liu Y, Li C, Deng W Clin Cosmet Investig Dermatol. 2025; 18():47-59.

PMID: 39802668 PMC: 11725243. DOI: 10.2147/CCID.S500654.


Co-evolution of glioma and immune microenvironment.

Elguindy M, Young J, Ho W, Lu R J Immunother Cancer. 2024; 12(12.

PMID: 39631850 PMC: 11624716. DOI: 10.1136/jitc-2024-009175.


Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma.

Chen Y, Wang K, Zhang X, Tao D, Shang Y, Wang P J Physiol Biochem. 2024; .

PMID: 39546272 DOI: 10.1007/s13105-024-01061-8.


Immunotherapy for glioblastoma: current state, challenges, and future perspectives.

Liu Y, Zhou F, Ali H, Lathia J, Chen P Cell Mol Immunol. 2024; 21(12):1354-1375.

PMID: 39406966 PMC: 11607068. DOI: 10.1038/s41423-024-01226-x.


Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.

Amin T, Hossain A, Jerin N, Mahmud I, Rahman M, Islam S Cancer Control. 2024; 31:10732748241290067.

PMID: 39353594 PMC: 11459535. DOI: 10.1177/10732748241290067.